Ardelyx, Inc.
Ardelyx, Inc. (Nasdaq: ARDX) is a commercial-stage biopharmaceutical company that develops and commercializes medicines for unmet medical needs. Its two marketed U.S. therapies contain tenapanor, an oral, minimally absorbed inhibitor of sodium/hydrogen exchanger 3 (NHE3). IBSRELA is approved to treat adults with… From the company’s description.
Over the twelve months to Sep 30, 2026, Ardelyx, Inc. reported revenue of $468.22M, up 17.6% from a year earlier, and a net loss of $55.47M. Its operating margin was −7.7%, and operations used $15.51M in cash. In fiscal 2025, it reported revenue of $407.32M, up 22.1% from fiscal 2024, and a net loss of $61.60M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Ardelyx, Inc. does
In the company’s own words
Ardelyx, Inc. (Nasdaq: ARDX) is a commercial-stage biopharmaceutical company that develops and commercializes medicines for unmet medical needs. Its two marketed U.S. therapies contain tenapanor, an oral, minimally absorbed inhibitor of sodium/hydrogen exchanger 3 (NHE3). IBSRELA is approved to treat adults with irritable bowel syndrome with constipation, while XPHOZAH is approved to reduce serum phosphorus in adults with chronic kidney disease on dialysis who have an inadequate response to phosphate binders or cannot tolerate them. Ardelyx is also conducting a Phase 3 trial of tenapanor for chronic idiopathic constipation and developing RDX10531, a next-generation NHE3 inhibitor. The company licenses tenapanor to partners for development and commercialization in Canada, Japan and China, and has a separate collaboration covering TGR5 agonist compounds. Ardelyx recognized its first U.S. sales of IBSRELA in 2022 and XPHOZAH in 2023. Its commercial portfolio is marketed under the IBSRELA and XPHOZAH brands.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- FREMONT, CA
- Fiscal year end
- December
- CIK
- 1437402
- SIC
- 2834
Financial performance, year by year
Fiscal 2014–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Ardelyx, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Ardelyx, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Ardelyx, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Ardelyx, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Ardelyx, Inc.'s last four quarterly filings that the numbers alone won't show?”